1183 Development of CTIM-76, a highly specific Claudin 6 bispecific antibody

• Kelly Byrnes-Blake,
• Kate Slovik,
• Joseph Rucker,
• Ileine Sanchez,
• Kyle Doolan,
• Breanna Tyrell,
• Anna Lobley,
• Nicholas Molino,
• Kristin Shema,
• Kyle Guldner,
• Hayley Roth,
• Alyssa Cunningham,
• Eric Butz,
• Stanley Roberts,
• Riley Payne,
• Ed Calamai,
• Ross Chambers

Affiliations

Kelly Byrnes-Blake

2Cascadia Drug Development Group, Seattle, WA, USA

Kate Slovik

3Carisma Therapeutics, Philadelphia, PA, USA

Joseph Rucker

1Integral Molecular, Philadelphia, PA, USA

Ileine Sanchez

1Integral Molecular, Philadelphia, PA, USA

Kyle Doolan

1Integral Molecular, Philadelphia, PA, USA

Breanna Tyrell

1Integral Molecular, Philadelphia, PA, USA

Anna Lobley

1Integral Molecular, Philadelphia, PA, USA

Nicholas Molino

1Integral Molecular, Philadelphia, PA, USA

Kristin Shema

1Integral Molecular, Philadelphia, PA, USA

Kyle Guldner

1Integral Molecular, Philadelphia, PA, USA

Hayley Roth

1Integral Molecular, Philadelphia, PA, USA

Alyssa Cunningham

1Integral Molecular, Philadelphia, PA, USA

Eric Butz

2Cascadia Drug Development Group, Seattle, WA, USA

Stanley Roberts

3SAR Safety Assessment, Northbrook, IL, USA

Riley Payne

1Integral Molecular, Philadelphia, PA, USA

Ed Calamai

4Context Therapeutics, Philadelphia, PA, USA

Ross Chambers

1Integral Molecular, Philadelphia, PA, USA